IP Library Granted Patent US 11,851,697
Granted Patent B2
US 11,851,697 · App. 17/573,110 · Granted Dec 26, 2023

Ex vivo protease activity detection for disease detection/diagnostic, staging, monitoring and treatment

Inventors: Faycal Touti (Belmont, MA); Wendy Winckler Adamovich (Melrose, MA); Sophie Cazanave (Cambridge, MA); Mehar Cheema (Medford, MA); Robert S. Langer (Newton, MA)
Assignee: Glympse Bio, Inc.
C12Q1/37G01N21/6428G01N33/542G01N33/573G01N33/582G01N2021/6432G01N2021/6439G01N2021/6441G01N2333/95G01N2800/085G01N2800/26G01N2800/7028
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,851,697
App. No.
17/573,110
Granted
Dec 26, 2023
Kind
B2
Abstract

The present application provides compositions and methods for determining a disease or condition in a subject. The method comprises contacting a body fluid with a molecule comprising a reporter thereof and the reported is cleaved by an agent in the body fluid. Diseases and conditions that can be determined by the method are also described.

Claims (26)

1. A method comprising:

contacting a plasma sample from a subject with a synthetic molecule ex vivo,

wherein said synthetic molecule comprises a reporter and a cleavable linker, and

wherein said synthetic molecule reacts with an agent from said plasma sample,

wherein said agent cleaves said cleavable linker causing said reporter to form a detectable signal,

introducing an anticoagulant to said plasma sample,

detecting a rate of formation or an amount of said detectable signal,

determining a disease condition based on said rate of formation or amount of said released reporter;

wherein said disease condition comprises a liver disease.

2. The method of claim 1 , wherein said cleavable linker is a peptide.

3. The method of claim 2 , wherein said peptide comprises an amino acid sequence selected from the group consisting of SEQ ID Nos: 1-677.

4. The method of claim 1 , wherein said cleavable linker is directly connected to said reporter through a covalent bond.

5. The method of claim 1 , wherein said anticoagulant is an EDTA, a citrate, a heparin, an oxalate, any salt, solvate, enantiomer, tautomer and geometric isomer thereof, or any mixtures thereof.

6. The method of claim 1 , wherein said agent is a protease.

7. The method of claim 6 , wherein said protease is an endopeptidase or an exopeptidase.

8. The method of claim 6 , wherein said protease is selected from the group consisting of an A20 (TNFa-induced protein 3), an abhydrolase domain containing 4, an abhydrolase domain containing 12, an abhydrolase domain containing 12B, an abhydrolase domain containing 13, an acrosin, an acylaminoacyl-peptidase, a disintegrin and metalloproteinase (ADAM), an ADAM1a, an ADAM2 (Fertilin-b), an ADAM3B, an ADAM4, an ADAM4B, an ADAMS, an ADAM6, an ADAM7, an ADAMS, an ADAMS, an ADAM10, an ADAM 11, an ADAM12 metalloprotease, an ADAM15, an ADAM17, an ADAM18, an ADAM19, an ADAM20, an ADAM21, an ADAM22, an ADAM23, an ADAM28, an ADAM29, an ADAM30, an ADAM32, an ADAM33, a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS), an ADAMTS1, an ADAMTS2, an ADAMTS3, an ADAMTS4, an ADAMTS5/11, an ADAMTS6, an ADAMTS7, an ADAMTS8, an ADAMTS9, an ADAMTS10, an ADAMTS12, an ADAMTS13, an ADAMTS14, an ADAMTS15, an ADAMTS16, an ADAMTS17, an ADAMTS18, an ADAMTS19, an ADAMTS20, an adipocyte-enh. binding protein 1, an Afg3-like protein 1, an Afg3-like protein 2, an airway-trypsin-like protease, an aminoacylase, an aminopeptidase A, an aminopeptidase B, an aminopeptidase B-like 1, an aminopeptidase MAMS/L-RAP, an aminopeptidase N, an aminopeptidase O, an aminopeptidase P homologue, an aminopeptidase P1, an aminopeptidase PILS, an aminopeptidase Q, an aminopeptidase-like 1, an AMSH/STAMBP, an AMSH- LP/STAMBPL1, an angiotensin-converting enzyme 1 (ACE1), an angiotensin-converting enzyme 2 (ACE2), an angiotensin-converting enzyme 3 (ACE3), an anionic trypsin (II), an apolipoprotein (a), an archaemetzincin-1, an archaemetzincin-2, an aspartoacylase, an aspartoacylase-3, an aspartyl aminopeptidase, an ataxin-3, an ataxin-3 like, an ATP/GTP binding protein 1, an ATP/GTP binding protein-like 2, an ATP/GTP binding protein-like 3, an ATP/GTP binding protein-like 4, an ATP/GTP binding protein-like 5, an ATP23 peptidase, an autophagin-1, an autophagin-2, an autophagin-3, an autophagin-4, an azurocidin, a beta lactamase, a beta-secretase 1, a beta-secretase 2, a bleomycin hydrolase, a brain serine proteinase 2, a BRCC36 (BRCA2-containing complex, sub 3), a calpain, a calpain 1, a calpain 2, a calpain 3, a calpain 4, a calpain 5, a calpain 6, a calpain 7, a calpain 7-like, a calpain 8, a calpain 9, a calpain 10, a calpain 11, a calpain 12, a calpain 13, a calpain 14, a calpain 15 (Solh protein), a cysteine protease, a carboxypeptidase A1, a carboxypeptidase A2, a carboxypeptidase A3, a carboxypeptidase A4, a carboxypeptidase A5, a carboxypeptidase A6, a carboxypeptidase B, a carboxypeptidase D, a carboxypeptidase E, a carboxypeptidase M, a carboxypeptidase N, a carboxypeptidase O, a carboxypeptidase U, a carboxypeptidase X1, a carboxypeptidase X2, a carboxypeptidase Z, a carnosine dipeptidase 1, a carnosine dipeptidase 2, a caspase recruitment domain family, member 8, a caspase, a caspase-1, a caspase-2, a caspase-3, a caspase-4/11, a caspase-5, a caspase-6, a caspase-7, a caspase-8, a caspase-9, a caspase-10, a caspase-12, a caspase-14, a caspase-14-like, a casper/FLIP, a cathepsin, a cathepsin A (CTSA), a cathepsin B (CTSB), a cathepsin C (CTSC), a cathepsin D (CTSD), a cathepsin E (CTSE), a cathepsin F, a cathepsin G, a cathepsin H (CTSH), a cathepsin K (CTSK), a cathepsin 1 (CTSL), a cathepsin L2, a cathepsin 0, a cathepsin S (CTSS), a cathepsin V (CTSV), a cathepsin W, a cathepsin Z (CTSZ), a cationic trypsin, a cezanne/OTU domain containing 7B, a cezanne-2, a CGI-58, a chymase, a chymopasin, a chymosin, a chymotrypsin B, a chymotrypsin C, a coagulation factor IXa, a coagulation factor VIIa, a coagulation factor Xa, a coagulation factor XIa, a coagulation factor XIIa, a collagenase 1, a collagenase 2, a collagenase 3, a complement protease C1r serine protease, a complement protease C1s serine protease, a complement C1r-homolog, a complement component 2, a complement component Cira, a complement component C1sa, a complement factor B, a complement factor D, a complement factor D-like, a complement factor I, a COPSE, a corin, a CSN5 (JAB1), a cylindromatosis protein, a cytosol alanyl aminopep.-like 1, a cytosol alanyl aminopeptidase, a DDI-related protease, a DECYSIN, a Derl-like domain family, member 1, a Derl-like domain family, member 2, a Derl-like domain family, member 3, a DESC1 protease, a desert hedgehog protein, a desumoylating isopeptidase 1, a desumoylating isopeptidase 2, a dihydroorotase, a dihydropyrimidinase, a dihydropyrimidinase-related protein 1, a dihydropyrimidinase-related protein 2, a dihydropyrimidinase-related protein 3, a dihydropyrimidinase-related protein 4, a dihydropyrimidinase-related protein 5, a DINE peptidase, a dipeptidyl peptidase (DPP), a dipeptidyl peptidase (DPP1), a dipeptidyl-peptidase 4 (DPP4), a dipeptidyl-peptidase 6 (DPP6), a dipeptidyl-peptidase 8 (DPP8), a dipeptidyl-peptidase 9 (DPP9), a dipeptidyl-peptidase II, a dipeptidyl-peptidase III, a dipeptidyl-peptidase 10 (DPP10), a DJ-1, a DNA-damage inducible protein, a DNA- damage inducible protein 2, a DUB-1, a DUB-2, a DUB2a, a DUB2a-like, a DUB2a-1ike2, a DUB6, or a combination thereof.

9. The method of claim 6 , wherein said protease is selected from the group consisting of a T cell protease, a complement protease, a fibrosis protease, and an inflammation-related protease.

10. The method of claim 1 , wherein said reporter comprises a fluorescent label.

11. The method of claim 10 , wherein said fluorescent label is selected from a group consisting a 5-carboxyfluorescein (5-FAM), a 7-amino-4-carbamoylmethylcoumarin (ACC), a 7-Amino-4-methylcoumarin (AMC), a 2-Aminobenzoyl (Abz), a Cy7, a Cy5, a Cy3 and a (5-((2-Aminoethyl)amino)naphthalene-l-sulfonic acid) (EDANS).

12. The method of claim 10 , wherein said synthetic molecule further comprises a fluorescent quencher.

13. The method of claim 12 , wherein said fluorescent quencher is selected from the group consisting of BHQO, BHQ1, BHQ2, BHQ3, BBQ650, ATTO 540Q, ATTO 580Q, ATTO 612Q, CPQ2, QSY-21, QSY-35, QSY-7, QSY-9, DABCYL (4-([4′-dimethylamino)phenyl]azo)benzoyl), Dnp (2,4-dinitrophenyl) and Eclipse.

14. The method of claim 1 , wherein said synthetic molecule further comprises a carrier.

15. The method of claim 14 , wherein said carrier comprises a native, labeled or synthetic protein, a synthetic chemical polymer of precisely known chemical composition or with a distribution around a mean molecular weight, an oligonucleotide, a phosphorodiamidate morpholino oligomer (PMO), a foldamer, a lipid, a lipid micelle, a nanoparticle, a solid support made of polystyrene, polypropylene or any other type of plastic, or any combination thereof.

16. The method of claim 1 , wherein said subject is a human subject.

17. The method of claim 1 , wherein said detection comprises a fluorescent detection.

18. The method of claim 17 , wherein said fluorescent detection is a fluorescence resonance energy transfer (FRET).

Assignments (3)
CHANGE OF NAME Recorded Jul 23, 2024
From: GLYMPSE BIO, INC.
To: SUNBIRD BIO, INC.
Reel/Frame 068494/0124 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 9, 2022
From: TOUTI, FAYCAL; ADAMOVICH, WENDY WINCKLER; CAZANAVE, SOPHIE; CHEEMA, MEHAR; LANGER, ROBERT S.
To: GLYMPSE BIO, INC.
Reel/Frame 062037/0243 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 26, 2022
From: TOUTI, FAYCAL; CAZANAVE, WENDY WINCKLER; CAZANAVE, SOPHIE; CHEEMA, MEHAR; LANGER, ROBERT S.
To: GLYMPSE BIO, INC.
Reel/Frame 058769/0659 →
Continuity (3)
Continuation In Part PCTUS2021049948 · Sep 10, 2021
Provisional Application 63077525 · Sep 11, 2020
Related Publication 20220128546A1 · Apr 28, 2022
Cited By (2)
US 12,305,217 US 12,492,422